X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (54) 54
humans (53) 53
pulmonary embolism (34) 34
female (33) 33
male (31) 31
prognosis (30) 30
aged (27) 27
middle aged (27) 27
risk assessment (24) 24
pulmonary embolism - diagnosis (22) 22
echocardiography (21) 21
management (21) 21
pulmonary embolism - mortality (21) 21
respiratory system (20) 20
risk factors (20) 20
cardiac & cardiovascular systems (19) 19
prospective studies (19) 19
aged, 80 and over (18) 18
risk stratification (18) 18
right-ventricular dysfunction (17) 17
hematology (15) 15
severity index (15) 15
acute disease (14) 14
diagnosis (14) 14
peripheral vascular disease (14) 14
european-society (13) 13
mortality (13) 13
pulmonary embolism - therapy (13) 13
biomarkers - blood (12) 12
metaanalysis (12) 12
pulmonary embolism - blood (12) 12
pulmonary embolism - drug therapy (12) 12
treatment outcome (12) 12
adult (11) 11
abridged index medicus (10) 10
cardiology (10) 10
deep-vein thrombosis (10) 10
embolisms (10) 10
guidelines (10) 10
normotensive patients (10) 10
prognostic value (10) 10
thrombolysis (10) 10
acid-binding protein (9) 9
algorithms (9) 9
anticoagulants - therapeutic use (9) 9
embolism (9) 9
risk (9) 9
severity of illness index (9) 9
validation (9) 9
venous thromboembolism (9) 9
fibrinolytic agents - therapeutic use (8) 8
natriuretic peptide (8) 8
roc curve (8) 8
thromboembolism (8) 8
biomarkers - metabolism (7) 7
blood pressure (7) 7
cardiovascular (7) 7
chronic thromboembolic pulmonary hypertension (7) 7
cohort studies (7) 7
hemodynamically stable patients (7) 7
lung (7) 7
predictive value of tests (7) 7
pulmonary embolism - complications (7) 7
pulmonary embolism - physiopathology (7) 7
stratification (7) 7
task-force (7) 7
thrombosis (7) 7
biomarkers (6) 6
brain natriuretic peptide (6) 6
critical care medicine (6) 6
fatty acid binding protein 3 (6) 6
follow-up studies (6) 6
pulmonary arteries (6) 6
recurrence (6) 6
reperfusion (6) 6
sensitivity and specificity (6) 6
anticoagulants (5) 5
cardiology esc (5) 5
heart (5) 5
hemodynamics (5) 5
heparin (5) 5
hypotension (5) 5
identification (5) 5
internal medicine (5) 5
regression analysis (5) 5
risk-factors (5) 5
stroke, systemic or venous thromboembolism (5) 5
thrombolytic therapy (5) 5
thrombolytic therapy - methods (5) 5
troponin (5) 5
troponin-t assay (5) 5
young adult (5) 5
bleeding (4) 4
cardiology and cardiovascular medicine (4) 4
complications (4) 4
computed tomography (4) 4
controlled clinical-trial (4) 4
controlled multicenter trial (4) 4
dysfunction (4) 4
europe (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Respiratory Journal, ISSN 0903-1936, 12/2017, Volume 50, Issue 6, pp. 1702386 - 1702386
Patients with pulmonary embolism (PE) represent a prognostically heterogeneous patient population. Therefore, the current European Society of Cardiology (ESC)... 
Medical imaging | Risk groups | Laboratories | Embolisms | Pulmonary arteries | Lung | Mortality | Embolism | Heart rate | Reperfusion | Computed tomography | Blood pressure | Ventricle | Health risk assessment | Heart diseases | Cancer
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 12, pp. 1536 - 1544
Abstract Background The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. Objectives This study investigated the long-term... 
Cardiovascular | Internal Medicine | chronic thromboembolic pulmonary hypertension | thrombolysis | long-term survival | pulmonary embolism | prognosis | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | GUIDELINES | CARDIOLOGY ESC | EUROPEAN-SOCIETY | TIME TRENDS | TRIAL | TASK-FORCE | HYPERTENSION | Pulmonary Embolism - prevention & control | Echocardiography | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Pulmonary Embolism - mortality | Fibrinolytic Agents - therapeutic use | Thrombolytic Therapy | Aged, 80 and over | Female | Aged | Tenecteplase | Pulmonary Embolism - diagnostic imaging | Pulmonary embolism | Stroke (Disease) | Medicine, Experimental | Medical research | Cardiology | Cardiovascular agents | Heart | Therapy | Chest | Lung | Incidence | Design | Computed tomography | Motivation | Tomography | Diagnosis | Thromboembolism | Anticoagulants | Pulmonary arteries | Mortality | Statistical tests | Patients | Fibrinolysis | Survival | Computation | Diagnostic software | Death | Health risk assessment | Risk management | Angiography | Arches | Embolisms | Medical services | Clinical trials | Population studies | Hemorrhage | Bleeding | Guidelines | Reperfusion | Risk assessment | Calcium-binding protein | Trends | Heart diseases | Injuries | Hypertension | Collapse | Stroke | Statistical analysis | Receiving | Steering | Complications | Risk reduction | Statistics | Pulmonary hypertension | Embolism | Computer programs | Contact | Thromboplastin | Medical prognosis | Fatalities | Ventricle | Heparin | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 15, pp. 1402 - 1411
In a randomized trial, 1006 patients with intermediate-risk pulmonary embolism were assigned to tenecteplase or placebo in addition to standard heparin... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | VENOUS THROMBOEMBOLISM | ELEVATION | COMPLICATIONS | ECHOCARDIOGRAPHY | THROMBOLYTIC THERAPY | RIGHT-VENTRICULAR ENLARGEMENT | PROGNOSTIC ROLE | Pulmonary Embolism - complications | Age Factors | Double-Blind Method | Humans | Middle Aged | Risk Factors | Heparin - therapeutic use | Male | Treatment Outcome | Tissue Plasminogen Activator - therapeutic use | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Pulmonary Embolism - mortality | Fibrinolytic Agents - adverse effects | Stroke - chemically induced | Fibrinolytic Agents - therapeutic use | Ventricular Dysfunction, Right - etiology | Aged, 80 and over | Troponin - blood | Female | Pulmonary Embolism - drug therapy | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Pulmonary embolism | Evaluation | Usage | Care and treatment | Fibrinolysis | Heart | Stroke | Heart attacks | Echocardiography | Embolisms | Pulmonary arteries | Lung | Hemorrhage | Bleeding | Embolism | Blood clots | Troponin T | Fibrin | Troponin | Troponin I | Motivation | Computed tomography | Ischemia | Calcium-binding protein | Heparin | Ventricle | Drug therapy | Index Medicus | Abridged Index Medicus | Ventricular Dysfunction, Right | Fibrinolytic Agents | Life Sciences | Tissue Plasminogen Activator | Pulmonary Embolism
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2010, Volume 55, Issue 19, pp. 2150 - 2157
Journal Article
Chest, ISSN 0012-3692, 2013, Volume 143, Issue 3, p. 873
Journal Article
Journal Article
Journal Article
European heart journal, ISSN 0195-668X, 05/2019
Pulmonary embolism (PE) is the third most common cardiovascular cause of death; systemic thrombolysis is potentially lifesaving treatment in patients... 
Journal Article
Journal Article
Journal Article
by Konstantinides, Stavros V and Torbicki, Adam and Agnelli, Giancarlo and Danchin, Nicolas and Fitzmaurice, David and Galiè, Nazzareno and Gibbs, J. Simon R and Huisman, Menno V and Humbert, Marc and Kucher, Nils and Lang, Irene and Lankeit, Mareike and Lekakis, John and Maack, Christoph and Mayer, Eckhard and Meneveau, Nicolas and Perrier, Arnaud and Pruszczyk, Piotr and Rasmussen, Lars H and Schindler, Thomas H and Svitil, Pavel and Vonk Noordegraaf, Anton and Zamorano, Jose Luis and Zompatori, Maurizio and Achenbach, Stephan and Baumgartner, Helmut and Bax, Jeroen J and Bueno, Hector and Dean, Veronica and Deaton, Christi and Erol, Cetin and Fagard, Robert and Ferrari, Roberto and Hasdai, David and Hoes, Arno and Kirchhof, Paulus and Knuuti, Juhani and Kolh, Philippe and Lancellotti, Patrizio and Linhart, Ales and Nihoyannopoulos, Petros and Piepoli, Massimo F and Ponikowski, Piotr and Sirnes, Per Anton and Tamargo, Juan Luis and Tendera, Michal and Wijns, William and Windecker, Stephan and Jimenez, David and Ageno, Walter and Agewall, Stefan and Asteggiano, Riccardo and Bauersachs, Rupert and Becattini, Cecilia and Bounameaux, Henri and Büller, Harry R and Davos, Constantinos H and Geersing, Geert-Jan and Sanchez, Miguel Angel Gómez and Heniks, Jeroen and Kilickap, Mustafa and Mareev, Viacheslav and Monreal, Manuel and Morais, Joao and Popescu, Bogdan A and Sanchez, Olivier and Spyropoulos, Alex C and Skoro-Sajer, Nika and Najafov, Ruslan and Sudzhaeva, Svetlana and de Pauw, Michel and Baraković, Fahir and Tokmakova, Mariya and Skoric, Bosko and Rokyta, Richard and Hansen, Morten Lock and Elmet, Märt and Harjola, Veli-Pekka and Meyer, Guy and Chukhrukidze, Archil and Rosenkranz, Stephan and Anoulakis, Aristides and Forster, Tamás and Fedele, Francesco and Sooronbaev, Talant and Maca, Aija and Ereminiene, Egle and Micallef, Josef and Aneasen, Arne and Kurzyna, Marcin and Ferreira, Daniel and Petris, Antoniu Octavian and Dzemeshkevich, Sergey and Asanin, Milika and Simkova, Iveta and Anguita, Manuel and Christersson, Christina and Kostova, Nela and Baccar, Hedi and Sade, Leyla Elif and ...
European heart journal, ISSN 0195-668X, 2014, Volume 35, Issue 43, pp. 3033 - 3080
Journal Article